Lipophilic Nanocrystal Prodrug-Release Defines the Extended Pharmacokinetic Profiles of a Year-Long Cabotegravir
N. Gauram, J. M. McMillan, D. Kumar, A. N. Bade, Q. Pan, T. A. Kulkarni, W. Li, N. A. Smith, B. L. Dyavar Shetty, B. Sillman, A. Szlachetka, B. J. Edagwa, H. E. Gendelman, Y. Alnouti
This study demonstrates that a nanoformulated CAB prodrug (NM2CAB) maintains plasma levels above the inhibitory concentration for up to one year, with sustained drug retention in tissues and macrophages.
Nature Communications · Jun 8, 2021Peer-reviewedPharmacology & Toxicology